News dal mondo

10

Apr

Contract manufacturing deals for drugs marketed in US shift to Europe

Biopharma companies are increasingly choosing to outsource manufacturing for the U.S. market to European facilities, finds data and analytics firm GlobalData.

Despite the Trump administration’s imposition of tariffs on European Union (EU) pharmaceuticals, biopharma companies are increasingly moving to outsource manufacturing for the U.S. market to facilities in Europe, according to an analysis by data and analytics firm GlobalData. 

Last year, the EU and U.S. announced a trade agreement that includes a 15% tariff on most EU exports, including brand name pharmaceuticals. However, GlobalData found that biopharma companies appear “undeterred” by the tariffs and are increasingly turning to contract manufacturing in Europe. ...[PharmaManufacturing]

 

 

08

Mag

Farmaceutica, Gemmato: 'per Testo unico deadline entro dicembre'

"Il Testo unico sulla legislazione farmaceutica, che ha come obiettivo quello compendiare 800 fra...

08

Mag

Min. Salute Gemmato: “Testo unico farmaceutico entro dicembre 2026”

Il sottosegretario alla Salute indica la tabella di marcia della riforma. Al centro accesso ai farmaci...

08

Mag

Precursori droghe: controllo esteso a 9 nuove sostanze dal 18 settembre 2026

Regolamento delegato (UE) 2026/314 della Commissione del 9 febbraio 2026 recante modifica del regolamento...

08

Mag

US FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight

The U.S. Food and Drug Administration (FDA) on Wednesday unveiled a one-day inspectional assessment...